Tivozanib: Completed Phase III enrollment

Aveo completed enrollment of 500 patients in an open-label, international Phase III trial comparing 1.5 mg oral tivozanib vs. 400 mg oral Nexavar sorafenib for 24 months. The company has exclusive ex...